A comparative review of escitalopram, paroxetine, and sertraline: Are they all alike?

International Clinical Psychopharmacology

Volumn 29, Issue 4, 2014, Pages 185-196

  Sanchez, Connie ^a   Reines, Elin H ^b   Montgomery, Stuart A ^c  

^a LUNDBECK RESEARCH USA   (United States)

^b H LUNDBECK A S   (Denmark)

^c IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

Author keywords

allosteric; escitalopram (S citalopram); major depressive disorder; paroxetine; selective serotonin reuptake inhibitor; serotonin; serotonin transporter; sertraline

Indexed keywords

ANTIDEPRESSANT AGENT; CYTOCHROME P450 2D6; ESCITALOPRAM; MUSCARINIC RECEPTOR; PAROXETINE; PLACEBO; SEROTONIN TRANSPORTER; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; CITALOPRAM; NERVE PROTEIN;

ALLOSTERISM; CONFUSION; CONGENITAL MALFORMATION; CONSTIPATION; DEPRESSION; DIARRHEA; DIZZINESS; DRUG BINDING SITE; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; HEADACHE; HUMAN; META ANALYSIS (TOPIC); NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEXUAL DYSFUNCTION; SIDE EFFECT; TREATMENT RESPONSE; TREMOR; WITHDRAWAL SYNDROME; XEROSTOMIA; ANIMAL; ANTAGONISTS AND INHIBITORS; BINDING SITE; BIOLOGICAL MODEL; CHEMISTRY; COMPARATIVE STUDY; DEPRESSIVE DISORDER, MAJOR; DRUG INTERACTION; EVIDENCE BASED MEDICINE; METABOLISM;

ALLOSTERIC SITE; ANIMALS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; CITALOPRAM; DEPRESSION; DEPRESSIVE DISORDER, MAJOR; DRUG INTERACTIONS; EVIDENCE-BASED MEDICINE; HUMANS; MODELS, BIOLOGICAL; NERVE TISSUE PROTEINS; PAROXETINE; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; SEROTONIN UPTAKE INHIBITORS; SERTRALINE;

EID: 84902165548     PISSN: 02681315     EISSN: 14735857     Source Type: Journal    
DOI: 10.1097/YIC.0000000000000023     Document Type: Review

References (92)

1. Aberg-Wistedt A, Agren H, Ekselius L, Bengtsson F, Akerblad AC (2000). Sertraline versus paroxetine in major depression: clinical outcome after six months of continuous therapy. J Clin Psychopharmacol 20:645-652.
2. Alex KD, Pehek EA (2007). Pharmacologic mechanisms of serotonergic regulation of dopamine neurotransmission. Pharmacol Ther 113:296-320. (Pubitemid 46149046)
3. Alexopoulos G, Gordon J, Zhang D (2004). A placebo-controlled trial of escitalopram and sertraline in the treatment of major depressive disorder. Neuropsychopharmacology 29 (Suppl):S87.
4. Arnt J, Christensen AV, Hyttel J (1985). Pharmacology in vivo of the phenylindan derivative, Lu 19-005, a new potent inhibitor of dopamine, noradrenaline and 5-hydroxytryptamine uptake in rat brain. Naunyn Schmiedebergs Arch Pharmacol 329:101-107. (Pubitemid 15078180)
5. Baldwin DS, Cooper JA, Huusom AK, Hindmarch I (2006). A double-blind, randomized, parallel-group, flexible-dose study to evaluate the tolerability, efficacy and effects of treatment discontinuation with escitalopram and paroxetine in patients with major depressive disorder. Int Clin Psychopharmacol 21:159-169. (Pubitemid 43740307)
6. Baldwin DS, Montgomery SA, Nil R, Lader M (2007a). Discontinuation symptoms in depression and anxiety disorders. Int J Neuropsychopharmacol 10:73-84. (Pubitemid 46122754)
7. Baldwin DS, Reines EH, Guiton C, Weiller E (2007b). Escitalopram therapy for major depression and anxiety disorders. Ann Pharmacother 41:1583-1592. (Pubitemid 47485624)
8. Blakely RD, Berson HE, Fremeau RT Jr, Caron MG, Peek MM, Prince HK, Bradley CC (1991). Cloning and expression of a functional serotonin transporter from rat brain. Nature 354:66-70. (Pubitemid 21896784)
9. Blier P, de Montigny C (1999). Serotonin and drug-induced therapeutic responses in major depression, obsessive-compulsive and panic disorders. Neuropsychopharmacology 21:91S-98S. (Pubitemid 29396476)
10. Bolden-Watson C, Richelson E (1993). Blockade by newly-developed antidepressants of biogenic amine uptake into rat brain synaptosomes. Life Sci 52:1023-1029.
11. Boos TL, Greiner E, Calhoun WJ, Prisinzano TE, Nightingale B, Dersch CM, et al. (2006). Structure-activity relationships of substituted N-benzyl piperidines in the GBR series: synthesis of 4-(2-(bis(4-fluorophenyl)methoxy) ethyl)-1-(2- trifluoromethylbenzyl)piperidine, an allosteric modulator of the serotonin transporter. Bioorg Med Chem 14:3967-3973.
12. Boulenger JP, Huusom AK, Florea I, Baekdal T, Sarchiapone M (2006). A comparative study of the efficacy of long-term treatment with escitalopram and paroxetine in severely depressed patients. Curr Med Res Opin 22:1331-1341. (Pubitemid 44085585)
13. Boulenger JP, Hermes A, Huusom AK, Weiller E (2010). Baseline anxiety effect on outcome of SSRI treatment in patients with severe depression: escitalopram vs paroxetine. Curr Med Res Opin 26:605-614.
14. Bourin M, Chue P, Guillon Y (2001). Paroxetine: a review. CNS Drug Rev 7:25-47. (Pubitemid 32280682)
15. Brennum LT, Sanchez C, Larsen AK, Cremers TI, Kreilgaard M, Thomsen C (2004). Escitalopram, paroxetine and sertraline, do they differ in their ability to inhibit serotonin transport? What can we learn from pre-clinical models? Eur Neuropsychopharmacol 14 (Suppl 3):S385.
16. Chen F, Larsen MB, Neubauer HA, Sanchez C, Plenge P, Wiborg O (2005a). Characterization of an allosteric citalopram-binding site at the serotonin transporter. J Neurochem 92:21-28. (Pubitemid 40193506)
17. Chen F, Larsen MB, Sanchez C, Wiborg O (2005b). The S-enantiomer of R,Scitalopram, increases inhibitor binding to the human serotonin transporter by an allosteric mechanism. Comparison with other serotonin transporter inhibitors. Eur Neuropsychopharmacol 15:193-198. (Pubitemid 40193425)
18. Cipriani A, Furukawa TA, Salanti G, Geddes JR, Higgins JP, Churchill R, et al. (2009). Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet 373:746-758.
19. Cipriani A, La FT, Furukawa TA, Signoretti A, Nakagawa A, Churchill R, et al. (2010). Sertraline versus other antidepressive agents for depression. Cochrane Database Syst Rev CD006117.
20. DeVane CL, Liston HL, Markowitz JS (2002). Clinical pharmacokinetics of sertraline. Clin Pharmacokinet 41:1247-1266. (Pubitemid 36026765)
21. El Mansari M, Sanchez C, Chouvet G, Renaud B, Haddjeri N (2005). Effects of acute and long-term administration of escitalopram and citalopram on serotonin neurotransmission: an in vivo electrophysiological study in rat brain. Neuropsychopharmacology 30:1269-1277. (Pubitemid 40848081)
22. El Mansari M, Wiborg O, Mnie-Filali O, Benturquia N, Sanchez C, Haddjeri N (2007). Allosteric modulation of the effect of escitalopram, paroxetine and fluoxetine: in-vitro and in-vivo studies. Int J Neuropsychopharmacol 10:31-40. (Pubitemid 46122750)
23. Fava M, Judge R, Hoog SL, Nilsson ME, Koke SC (2000a). Fluoxetine versus sertraline and paroxetine in major depressive disorder: changes in weight with long-term treatment. J Clin Psychiatry 61:863-867.
24. Fava M, Rosenbaum JF, Hoog SL, Tepner RG, Kopp JB, Nilsson ME (2000b). Fluoxetine versus sertraline and paroxetine in major depression: tolerability and efficacy in anxious depression. J Affect Disord 59:119-126. (Pubitemid 30317428)
25. Fava M, Hoog SL, Judge RA, Kopp JB, Nilsson ME, Gonzales JS (2002). Acute efficacy of fluoxetine versus sertraline and paroxetine in major depressive disorder including effects of baseline insomnia. J Clin Psychopharmacol 22:137-147. (Pubitemid 34289388)
26. Fujishiro J, Imanishi T, Onozawa K, Tsushima M (2002). Comparison of the anticholinergic effects of the serotonergic antidepressants, paroxetine, fluvoxamine and clomipramine. Eur J Pharmacol 454:183-188. (Pubitemid 35287477)
27. Gartlehner G, Hansen RA, Morgan LC, Thaler K, Lux L, Van NM, et al. (2011). Comparative benefits and harms of second-generation antidepressants for treating major depressive disorder: an updated meta-analysis. Ann Intern Med 155:772-785.
28. Gibiino S, Serretti A (2012). Paroxetine for the treatment of depression: a critical update. Expert Opin Pharmacother 13:421-431.
29. Gillman PK (2007). Tricyclic antidepressant pharmacology and therapeutic drug interactions updated. Br J Pharmacol 151:737-748. (Pubitemid 47075311)
30. Glazer WM (2000). Extrapyramidal side effects, tardive dyskinesia, and the concept of atypicality. J Clin Psychiatry 61 (Suppl 3):16-21. (Pubitemid 30155229)
31. Grimsley SR, Jann MW (1992). Paroxetine, sertraline, and fluvoxamine: new selective serotonin reuptake inhibitors. Clin Pharm 11:930-957.
32. Hiemke C, Hartter S (2000). Pharmacokinetics of selective serotonin reuptake inhibitors. Pharmacol Ther 85:11-28.
33. Johnson AM (1992). Paroxetine: a pharmacological review. Int Clin Psychopharmacol 6 (Suppl 4):15-24.
34. Kane JM (2011). Addressing side effects from antipsychotic treatment in schizophrenia. J Clin Psychiatry 72:e07.
35. Kasper S, Spadone C, Verpillat P, Angst J (2006). Onset of action of escitalopram compared with other antidepressants: results of a pooled analysis. Int Clin Psychopharmacol 21:105-110. (Pubitemid 43740318)
36. Kasper S, Baldwin DS, Larsson LS, Boulenger JP (2009a). Superiority of escitalopram to paroxetine in the treatment of depression. Eur Neuropsychopharmacol 19:229-237.
37. Kasper S, Sacher J, Klein N, Mossaheb N, Attarbaschi-Steiner T, Lanzenberger R, et al. (2009b). Differences in the dynamics of serotonin reuptake transporter occupancy may explain superior clinical efficacy of escitalopram versus citalopram. Int Clin Psychopharmacol 24:119-125.
38. Kennedy SH, Andersen HF, Lam RW (2006). Efficacy of escitalopram in the treatment of major depressive disorder compared with conventional selective serotonin reuptake inhibitors and venlafaxine XR: a meta-analysis. J Psychiatry Neurosci 31:122-131.
39. Kennedy SH, Andersen HF, Thase ME (2009). Escitalopram in the treatment of major depressive disorder: a meta-analysis. Curr Med Res Opin 25:161-175.
40. Kitaichi Y, Inoue T, Nakagawa S, Boku S, Kakuta A, Izumi T, Koyama T (2010). Sertraline increases extracellular levels not only of serotonin, but also of dopamine in the nucleus accumbens and striatum of rats. Eur J Pharmacol 647:90-96.
41. Lam RW, Kennedy SH, Grigoriadis S, McIntyre RS, Milev R, Ramasubbu R, et al. (2009). Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. III. Pharmacotherapy. J Affect Disord 117 (Suppl 1):S26-S43.
42. Lam RW, Lonn SL, Despiegel N (2010). Escitalopram versus serotonin noradrenaline reuptake inhibitors as second step treatment for patients with major depressive disorder: a pooled analysis. Int Clin Psychopharmacol 25:199-203.
43. Larsen AK, Brennum LT, Egebjerg J, Sanchez C, Halldin C, Andersen PH (2004). Selectivity of (3)H-MADAM binding to 5-hydroxytryptamine transporters in vitro and in vivo in mice; correlation with behavioural effects. Br J Pharmacol 141:1015-1023. (Pubitemid 38510085)
44. Lepola U, Wade A, Andersen HF (2004). Do equivalent doses of escitalopram and citalopram have similar efficacy? A pooled analysis of two positive placebo-controlled studies in major depressive disorder. Int Clin Psychopharmacol 19:149-155. (Pubitemid 38586486)
45. MacQueen G, Born L, Steiner M (2001). The selective serotonin reuptake inhibitor sertraline: its profile and use in psychiatric disorders. CNS Drug Rev 7:1-24. (Pubitemid 32280681)
46. Madhusoodanan S, Alexeenko L, Sanders R, Brenner R (2010). Extrapyramidal symptoms associated with antidepressants - a review of the literature and an analysis of spontaneous reports. Ann Clin Psychiatry 22:148-156.
47. Marks DM, Park MH, Ham BJ, Han C, Patkar AA, Masand PS, Pae CU (2008). Paroxetine: safety and tolerability issues. Expert Opin Drug Saf 7: 783-794.
48. Meijer WE, Heerdink ER, van Eijk JT, Leufkens HG (2002). Adverse events in users of sertraline: results from an observational study in psychiatric practice in the Netherlands. Pharmacoepidemiol Drug Saf 11:655-662. (Pubitemid 35469360)
49. Meyer JH,Wilson AA, Sagrati S, Hussey D, Carella A, Potter WZ, et al. (2004). Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses: an [11C]DASB positron emission tomography study. Am J Psychiatry 161:826-835. (Pubitemid 38625335)
50. Mnie-Filali O, Faure C, El Mansari M, Lambas-Senas L, Berod A, Zimmer L, et al. (2007). R-citalopram prevents the neuronal adaptive changes induced by escitalopram. Neuroreport 18:1553-1556. (Pubitemid 47476382)
51. Montgomery S, Hansen T, Kasper S (2011). Efficacy of escitalopram compared to citalopram: a meta-analysis. Int J Neuropsychopharmacol 14:261-268.
52. Montgomery SA, Baldwin DS, Blier P, Fineberg NA, Kasper S, Lader M, et al. (2007). Which antidepressants have demonstrated superior efficacy? A review of the evidence. Int Clin Psychopharmacol 22:323-329. (Pubitemid 47530836)
53. Montgomery SA, Moller HJ (2009). Is the significant superiority of escitalopram compared with other antidepressants clinically relevant? Int Clin Psychopharmacol 24:111-118.
54. Nandi A, Dersch CM, Kulshrestha M, Ananthan S, Rothman RB (2004). Identification and characterization of a novel allosteric modulator (SoRI- 6238) of the serotonin transporter. Synapse 53:176-183. (Pubitemid 38971896)
55. Nightingale B, Dersch CM, Boos TL, Greiner E, Calhoun WJ, Jacobson AE, et al. (2005). Studies of the biogenic amine transporters. XI. Identification of a 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine (GBR12909) analog that allosterically modulates the serotonin transporter. J Pharmacol Exp Ther 314:906-915. (Pubitemid 41043877)
56. Nutt DJ, Feetam CL (2010). What one hand giveth the other taketh away: some unpredicted effects of enantiomers in psychopharmacology. J Psychopharmacol 24:1137-1141.
57. Owens MJ, Morgan WN, Plott SJ, Nemeroff CB (1997). Neurotransmitter receptor and transporter binding profile of antidepressants and their metabolites. J Pharmacol Exp Ther 283:1305-1322. (Pubitemid 28016506)
58. Owens MJ, Knight DL, Nemeroff CB (2001). Second-generation SSRIs: human monoamine transporter binding profile of escitalopram and R-fluoxetine. Biol Psychiatry 50:345-350. (Pubitemid 32816947)
59. Pae CU, Patkar AA (2007). Paroxetine: current status in psychiatry. Expert Rev Neurother 7:107-120. (Pubitemid 46434161)
60. Petit A, Piednoir D, Germain ML, Trenque T (2003). Drug-induced hyperprolactinemia: a case-non-case study from the national pharmacovigilance database. Therapie 58:159-163. (Pubitemid 36958850)
61. Plenge P, Mellerup ET (1997). An affinity-modulating site on neuronal monoamine transport proteins. Pharmacol Toxicol 80:197-201. (Pubitemid 27168868)
62. Preskorn SH (2012). The use of biomarkers in psychiatric research: how serotonin transporter occupancy explains the dose-response curves of SSRIs. J Psychiatr Pract 18:38-45.
63. Ramsberg J, Asseburg C, Henriksson M (2012). Effectiveness and costeffectiveness of antidepressants in primary care: a multiple treatment comparison meta-analysis and cost-effectiveness model. PLoS One 7:e42003.
64. Rao N (2007). The clinical pharmacokinetics of escitalopram. Clin Pharmacokinet 46:281-290. (Pubitemid 46507007)
65. Richelson E (2001). Pharmacology of antidepressants. Mayo Clin Proc 76: 511-527. (Pubitemid 32423135)
66. Richelson E (2003). Interactions of antidepressants with neurotransmitter transporters and receptors and their clinical relevance. J Clin Psychiatry 64 (Suppl 13):5-12. (Pubitemid 37267809)
67. Sanchez C (2002). Escitalopram, a super selective serotonin reuptake inhibitor - in vivo. Nord J Psychiatry 56:115-115.
68. Sanchez C (2006). The pharmacology of citalopram enantiomers: the antagonism by R-citalopram on the effect of S-citalopram. Basic Clin Pharmacol Toxicol 99:91-95. (Pubitemid 44213936)
69. Sanchez C, Meier E (1997). Behavioral profiles of SSRIs in animal models of depression, anxiety and aggression. Are they all alike? Psychopharmacology (Berl) 129:197-205. (Pubitemid 27085389)
70. Sanchez C, Larsen AK, Gupta S (2002). Escitalopram, the most selective serotonin reuptake inhibitor - in vitro data. Nord J Psychiatry 56:115.
71. Sanchez C, Bergqvist PB, Brennum LT, Gupta S, Hogg S, Larsen A, Wiborg O (2003). Escitalopram, the S-(+)-enantiomer of citalopram, is a selective serotonin reuptake inhibitor with potent effects in animal models predictive of antidepressant and anxiolytic activities. Psychopharmacology (Berl) 167:353-362. (Pubitemid 36754236)
72. Sanchez C, Bogeso KP, Ebert B, Reines EH, Braestrup C (2004). Escitalopram versus citalopram: the surprising role of the R-enantiomer. Psychopharmacology (Berl) 174:163-176. (Pubitemid 38916289)
73. Schillevoort I, van Puijenbroek EP, de BA, Roos RA, Jansen PA, Leufkens HG (2002). Extrapyramidal syndromes associated with selective serotonin reuptake inhibitors: a case-control study using spontaneous reports. Int Clin Psychopharmacol 17:75-79. (Pubitemid 34169650)
74. Serretti A, Chiesa A (2009). Treatment-emergent sexual dysfunction related to antidepressants: a meta-analysis. J Clin Psychopharmacol 29:259-266.
75. Sogaard B, Mengel H, Rao N, Larsen F (2005). The pharmacokinetics of escitalopram after oral and intravenous administration of single and multiple doses to healthy subjects. J Clin Pharmacol 45:1400-1406. (Pubitemid 41642443)
76. Spina E, Trifiro G, Caraci F (2012). Clinically significant drug interactions with newer antidepressants. CNS Drugs 26:39-67.
77. Tatsumi M, Groshan K, Blakely RD, Richelson E (1997). Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol 340:249-258. (Pubitemid 28022649)
78. Thase ME, Haight BR, Richard N, Rockett CB, Mitton M, Modell JG, et al. (2005). Remission rates following antidepressant therapy with bupropion or selective serotonin reuptake inhibitors: a meta-analysis of original data from 7 randomized controlled trials. J Clin Psychiatry 66:974-981. (Pubitemid 41191788)
79. Trenque T, Herlem E, Auriche P, Drame M (2011). Serotonin reuptake inhibitors and hyperprolactinaemia: a case/non-case study in the French pharmacovigilance database. Drug Saf 34:1161-1166.
80. Tuppurainen H, Kuikka JT, Viinamaki H, Husso M, Tiihonen J (2010). Extrapyramidal side-effects and dopamine D(2/3) receptor binding in substantia nigra. Nord J Psychiatry 64:233-238.
81. Undurraga J, Baldessarini RJ (2012). Randomized, placebo-controlled trials of antidepressants for acute major depression: thirty-year meta-analytic review. Neuropsychopharmacology 37:851-864.
82. Ventura D, Armstrong EP, Skrepnek GH, Haim EM (2007). Escitalopram versus sertraline in the treatment of major depressive disorder: a randomized clinical trial. Curr Med Res Opin 23:245-250. (Pubitemid 46333371)
83. Voineskos AN, Wilson AA, Boovariwala A, Sagrati S, Houle S, Rusjan P, et al. (2007). Serotonin transporter occupancy of high-dose selective serotonin reuptake inhibitors during major depressive disorder measured with [11C]DASB positron emission tomography. Psychopharmacology (Berl) 193:539-545. (Pubitemid 47094376)
84. Wade A, Andersen HF (2006). The onset of effect for escitalopram and its relevance for the clinical management of depression. Curr Med Res Opin 22: 2101-2110. (Pubitemid 44789974)
85. Wade AG, Fernandez JL, Francois C, Hansen K, Danchenko N, Despiegel N (2008). Escitalopram and duloxetine in major depressive disorder: a pharmacoeconomic comparison using UK cost data. Pharmacoeconomics 26:969-981.
86. Wennogle LP, Meyerson LR (1982). Serotonin modulates the dissociation of [3H]imipramine from human platelet recognition sites. Eur J Pharmacol 86:303-307. (Pubitemid 13220934)
87. Wolkowitz OM,Wolf J, Shelly W, Rosser R, Burke HM, Lerner GK, et al. (2011). Serum BDNF levels before treatment predict SSRI response in depression. Prog Neuropsychopharmacol Biol Psychiatry 35:1623-1630.
88. Yasui-Furukori N, Tsuchimine S, Nakagami T, Fujii A, Sato Y, Tomita T, et al. (2011). Association between plasma paroxetine concentration and changes in plasma brain-derived neurotrophic factor levels in patients with major depressive disorder. Hum Psychopharmacol 26:194-200.
89. Yoshimura R, Ikenouchi-Sugita A, Hori H, Umene-NakanoW, Hayashi K, Katsuki A, et al. (2010). Blood levels of brain-derived neurotrophic factor (BDNF) in major depressive disorder. Seishin Shinkeigaku Zasshi 112:982-985.
90. Zhong H, Hansen KB, Boyle NJ, Han K, Muske G, Huang X, et al. (2009). An allosteric binding site at the human serotonin transporter mediates the inhibition of escitalopram by R-citalopram: kinetic binding studies with the ALI/VFL-SI/TT mutant. Neurosci Lett 462:207-212.
91. Zhong H, Haddjeri N, Sanchez C (2012a). Escitalopram, an antidepressant with an allosteric effect at the serotonin transporter - a review of current understanding of its mechanism of action. Psychopharmacology (Berl) 219:1-13.
92. Zhong H, Sanchez C, Caron MG (2012b). Consideration of allosterism and interacting proteins in the physiological functions of the serotonin transporter. Biochem Pharmacol 83:435-442.